HRTX today
$0.36-$0.01 (-3.96%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourExpanding
1 hourStrong Bullish
15 minSymmetric Triangle
5 minExpanding
Daily trend turns up above $0.35
Key levels
Resistance$0.54
Resistance$0.43
Support$0.32
Support$0.27
Latest news & SEC filings
SEC FilingHeron Therapeutics, Inc. filed an insider trading report (Form 4)
DealCorMedix Therapeutics agrees to buy most of Heron Therapeutics' assets
EarningsHeron Therapeutics posts $0.03 per-share loss as quarterly revenue falls short
All HRTX news →About Heron Therapeutics
Heron Therapeutics develops and sells medicines for patients receiving surgery or cancer treatment. Its acute care offerings include ZYNRELEF for postsurgical pain and APONVIE for nausea and vomiting after operations. For oncology, it provides CINVANTI and SUSTOL to prevent nausea and vomiting caused by chemotherapy. The company distributes its products in the United States through specialty distributors and wholesalers that supply hospitals and clinics.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
HERON THERAPEUTICS, INC. /DE/ (HRTX)
What Is the Price Target for HRTX?
SEPT Low Target
$2.00
SEPT Mid Target
$2.00
SEPT High Target
$2.00
Analyst Consensus
$2.00
Is HRTX a Buy or Sell Right Now?
Thesis
- •Revenue growing 7.4% YoY with STABLE trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for HRTX.
Start Free Trial →Is HRTX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$1.52
28
Moat Score
NONE
3/9
Piotroski Score
-9.3
Altman Z-Score
What Is Smart Money Doing with HRTX?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Hensley Mark Earl | officer | Buy | 31,250 | - | Nov 6, 2026 |
| Hensley Mark Earl | officer | Sale | 8,889 | $3K | Nov 6, 2026 |
| Collard Craig A | director officer | Buy | 34,788 | - | Oct 31, 2026 |
| Collard Craig A | director officer | Sale | 8,471 | $2K | Oct 31, 2026 |
| Duarte Ira | officer | Buy | 11,695 | - | Oct 31, 2026 |
| Duarte Ira | officer | Sale | 3,327 | $931.56 | Oct 31, 2026 |
| Forbes William P | officer | Buy | 11,695 | - | Oct 31, 2026 |
| Forbes William P | officer | Sale | 3,327 | $931.56 | Oct 31, 2026 |
| Collard Craig A | director officer | Buy | 50,021 | - | Oct 30, 2026 |
| Collard Craig A | director officer | Sale | 12,181 | $3K | Oct 30, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →HRTX Growth Story
Revenue YoY
7.4%
3yr Revenue CAGR
12.9%
EPS Growth YoY
-33.33%
FCF Growth YoY
-15.2%
Revenue Trend
STABLE
Dark Pool Trades for HRTX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for HRTX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 13:05:47 | $0.35 | 1,200 | $$426 | SELL |
| 13:00:21 | $0.37 | 2,749 | $$1K | BUY |
| 12:48:51 | $0.35 | 30,000 | $$11K | SELL |
| 12:47:50 | $0.36 | 3,200 | $$1K | BUY |
| 12:47:50 | $0.35 | 3,650 | $$1K | SELL |
5 dark pool trades shown · $$14K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for HERON THERAPEUTICS, INC. /DE/ (HRTX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →HRTX — frequently asked questions
What is HRTX stock price today?
HERON THERAPEUTICS, INC. /DE/ (HRTX) is at $0.36, down 3.96% (-$0.01) at the Nov 11, 2026 close.
Why is HRTX stock moving today?
Latest HRTX news — Nov 10, 2026: Heron Therapeutics, Inc. filed an insider trading report (Form 4) · Nov 9, 2026: CorMedix Therapeutics agrees to buy most of Heron Therapeutics' assets
What is the HRTX price target?
The average analyst price target for HRTX is $2.00, ranging from $2 to $2, based on 1 analysts. Latest: HC Wainwright & Co. maintains on Jun 3, 2026.
What do analysts rate HRTX?
Analyst ratings for HRTX: 0 Buy, 1 Hold, 2 Sell — consensus Sell.
Did HRTX beat earnings?
HRTX last reported on Aug 10, 2026: EPS -$0.03 vs -$0.01 expected — a miss of 500.0%.
Does HRTX pay a dividend?
HRTX does not currently pay a dividend.
What are HRTX support and resistance levels?
Support: $0.32, $0.27. Resistance: $0.43, $0.54, $0.76.
What are insiders doing with HRTX?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on HRTX?
Nov 10, 2026: Heron Therapeutics, Inc. filed an insider trading report (Form 4) · Nov 9, 2026: CorMedix Therapeutics agrees to buy most of Heron Therapeutics' assets · Nov 9, 2026: Heron Therapeutics posts $0.03 per-share loss as quarterly revenue falls short